On March 31, 2023 at 14:16:36 ET an unusually large
$659.70K block of Call contracts in Viking Therapeutics
(VKTX) was bought,
with a strike price of $17.00 / share, expiring in 77 days (on June 16, 2023).
Fintel tracks all large options trades, and the premium spent on this trade was 2.27 sigmas above the mean, placing it in the 98.77 percentile of all recent large trades made in VKTX options.
This trade was first picked up on Fintel’s real time Unusual Option Trades
tool, where unusual option trades are highlighted.
Analyst Price Forecast Suggests 14.77% Upside
As of March 30, 2023,
the average one-year price target for Viking Therapeutics is $19.89.
The forecasts range from a low of $12.12 to a high of $31.50.
The average price target represents an increase of 14.77% from its latest reported closing price of $17.33.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Viking Therapeutics
is $0MM.
The projected annual non-GAAP EPS
is -$1.01.
What is the Fund Sentiment?
There are 188 funds or institutions reporting positions in Viking Therapeutics.
This is an increase
of
21
owner(s) or 12.57% in the last quarter.
Average portfolio weight of all funds dedicated to VKTX is 0.08%,
an increase
of 397.75%.
Total shares owned by institutions increased
in the last three months by 28.17% to 35,133K shares.
The put/call ratio of VKTX is 0.26, indicating a
bullish
outlook.
What are Large Shareholders Doing?
Millennium Management
holds 4,382K shares
representing 5.59% ownership of the company.
In it’s prior filing, the firm reported owning 3,103K shares, representing
an increase
of 29.19%.
The firm
increased
its portfolio allocation in VKTX by 356.66% over the last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares
holds 2,231K shares
representing 2.85% ownership of the company.
No change in the last quarter.
Boxer Capital
holds 1,500K shares
representing 1.91% ownership of the company.
In it’s prior filing, the firm reported owning 0K shares, representing
an increase
of 100.00%.
Laurion Capital Management
holds 1,299K shares
representing 1.66% ownership of the company.
No change in the last quarter.
Great Point Partners
holds 1,295K shares
representing 1.65% ownership of the company.
Viking Therapeutics Background Information
(This description is provided by the company.)
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives. The company’s clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1 first-in-human clinical trial. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
